Facial Angiofibroma

Also known as: Facial Angiofibromas / Angiofibroma of Face / Angiofibromas of the face / Fibrous skin tumor of tuberous sclerosis (disorder) / Adenoma Sebaceum / Fibrous papule of face (disorder)

Drug	Drug Name	Drug Description
DB00877	Sirolimus	An mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.

Drug	Drug Name	Target	Type
DB00877	Sirolimus	Cytochrome P450 3A4	enzyme
DB00877	Sirolimus	Serine/threonine-protein kinase mTOR	target
DB00877	Sirolimus	Cytochrome P450 3A5	enzyme
DB00877	Sirolimus	Cytochrome P450 3A7	enzyme
DB00877	Sirolimus	P-glycoprotein 1	transporter
DB00877	Sirolimus	Solute carrier organic anion transporter family member 1B1	transporter
DB00877	Sirolimus	Multidrug and toxin extrusion protein 1	transporter
DB00877	Sirolimus	Serum albumin	carrier
DB00877	Sirolimus	Alpha-1-acid glycoprotein 1	carrier
DB00877	Sirolimus	Apolipoproteins	carrier

Drug	Drug Name	Phase	Status	Count
DB00877	Sirolimus	1	Completed	1
DB00877	Sirolimus	2	Terminated	1
DB01590	Everolimus	2 / 3	Withdrawn	1
DB00877	Sirolimus	2 / 3	Completed	1
DB00136	Calcitriol	3	Completed	1
DB00877	Sirolimus	3	Completed	1